> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Discuss Amylyx NDA for ALS
- URL: https://www.fdaweb.com/panel-to-discuss-amylyx-nda-for-als/
- Published: 2022-02-17T12:00:00.000Z
- Updated: 2026-09-14T17:33:10.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5151186

*Federal Register* notice: FDA has announced a 3/30 Peripheral and Central Nervous System Drugs Advisory Committee. The general function of the committee is to provide advice and recommendations to FDA on regulatory issues. Panel members are scheduled to discuss an Amylyx Pharmaceuticals NDA for sodium phenylbutyrate/taurursodiol (AMX0035) powder for oral suspension, indicated for treating amyotrophic lateral sclerosis. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-02-17/pdf/2022-03430.pdf?ref=fdaweb.com).